The Science Behind Why Ketamine Works — And Why It Matters Now
A newly published review in Psychiatric Times (April 2026) brings fresh clinical weight to something ketamine patients have known experientially for years: when traditional antidepressants fail, targeting the glutamatergic system can produce rapid, meaningful relief. The article focuses on two primary agents — esketamine (Spravato) and dextromethorphan-bupropion (Auvelity) — as the vanguard of glutamate-based treatment for treatment-resistant depression (TRD). But the broader story here is about the glutamate system itself, and understanding it helps oral ketamine users better contextualize their own treatment.
Traditional antidepressants work on monoamine neurotransmitters — serotonin, norepinephrine, dopamine. They take weeks to work, and for roughly 30% of people with major depressive disorder, they don't work at all. That population, defined clinically as having TRD after failing two or more adequate antidepressant trials, is precisely who glutamate-targeting therapies are designed to serve. The review explains that ketamine and its analogs work by blocking NMDA receptors and triggering a downstream surge in AMPA receptor activity, ultimately promoting synaptogenesis — the growth of new synaptic connections in brain regions like the prefrontal cortex that are structurally degraded by chronic depression.
This synaptic repair mechanism explains why ketamine can produce antidepressant effects within hours rather than weeks. It is not simply a mood-altering drug — it is, in the framework of current neuroscience, a synaptogenic agent.
Oral Ketamine Tablets in the Glutamate Conversation
The Psychiatric Times review centers on esketamine nasal spray and the DXM-bupropion combination pill, but racemic ketamine — including oral tablet formulations — operates through the same fundamental glutamatergic mechanism. For patients using compounded oral ketamine tablets, this research provides important scientific grounding for why the treatment works, even if the delivery method differs significantly from what was studied.
Delivery method matters enormously when it comes to glutamate-targeting therapies. Esketamine nasal spray delivers the drug with relatively predictable bioavailability and is administered in a clinical setting with post-dose monitoring. IV ketamine infusions provide the highest and most controllable plasma levels. Sublingual troches occupy a middle ground — absorbed partly through the oral mucosa for faster onset, partly swallowed for slower absorption. Oral tablets, by contrast, are almost entirely absorbed through the gastrointestinal tract, meaning they pass through first-pass hepatic metabolism before reaching systemic circulation.
What this means practically: oral ketamine tablets typically produce lower peak plasma concentrations than IV or nasal routes, and the onset is slower — generally 30 to 60 minutes versus minutes for IV. The norketamine metabolite, which has its own antidepressant properties and a longer half-life than ketamine itself, plays a proportionally larger role in the therapeutic effect when ketamine is taken orally. Some clinicians believe this metabolite profile actually contributes to the more sustained mood-lifting effects some patients report with oral dosing, even if the acute dissociative experience is less pronounced.
Dosing protocols for oral tablets must account for this pharmacokinetic reality. Providers typically prescribe higher oral doses than IV doses to compensate for reduced bioavailability — but titration is still essential, and patients should never self-adjust doses without clinical guidance. The therapeutic window for ketamine is real: too little produces insufficient glutamatergic activation, while too much increases risks of dissociation, cardiovascular effects, and over time, potential tolerance or dependence concerns.
Key Takeaway
Oral ketamine tablets work through the same glutamate-NMDA mechanism highlighted in this research — but their lower bioavailability and slower absorption profile mean dosing cannot be directly compared to IV or nasal esketamine. Always follow your prescriber's titration protocol and report both insufficient response and side effects promptly. The goal is synaptogenesis, not sedation.
Access, Oversight, and What the TRD Research Push Means for Patients
The growing body of peer-reviewed literature on glutamatergic treatments — including this Psychiatric Times review — is significant for the broader ketamine access landscape. As esketamine and ketamine accumulate clinical evidence, insurers and regulators become more familiar with the mechanism and the treatment category. This can work in favor of patients seeking oral ketamine access, as prescribers have stronger evidentiary ground to stand on when justifying treatment to payers or institutional review boards.
At the same time, the review's emphasis on clinical oversight is worth noting. Both esketamine (via the REMS program) and IV ketamine are administered with direct provider supervision and post-dose monitoring windows. Oral ketamine at home occupies a different regulatory and safety space — one that places more responsibility on the patient and their prescribing provider to establish appropriate safeguards. Reputable oral ketamine programs include pre-treatment psychological screening, structured dosing schedules, integration support, and regular check-ins. If yours doesn't, that's worth a conversation with your provider.
The expanding research attention on TRD and glutamate pathways also signals that this field is not standing still. Newer NMDA-targeting compounds are in trials, and understanding of optimal dosing frequency, maintenance strategies, and combination approaches continues to evolve. For oral ketamine users, staying informed through clinical sources — rather than anecdote-driven forums alone — is increasingly important as the treatment landscape matures.
Read the full review at Psychiatric Times.
Share